Interpace Biosciences has filed a notice of an exempt offering of securities to raise $47 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Interpace Biosciences is raising up to $47,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Thomas Burnell…